.
MergerLinks Header Logo

New Deal


Announced

PAI Partners-backed Ethypharm acquired Pharmy II Laboratory.

Financials

Edit Data
Transaction Value-
Consideration Type-
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

France

Pending

pharmaceutical company

Private

Pharmaceuticals

Acquisition

Private Equity

pharmaceutical

Single Bidder

Synopsis

Edit

The Ethypharm Group has acquired the PHARMY II Laboratory. Financial terms were not disclosed. Pharmy II is a pharmaceutical operating company founded in France in 1982. Well established in France, the Pharmy II laboratory is specialized in the treatment of pain and more particularly mechanical musculo-articular pain. It provides health professionals - rheumatologist, mesotherapist, sports doctor - and their patients, on the French market, a range of solutions intended to be injected locally, by the technique of mesotherapy. Through this acquisition, Ethypharm is expanding its portfolio of six drugs and completing its range of proprietary medicinal products in both injectable and liquid form. "By becoming part of a new "specialized" market, Ethypharm is strengthening its commitment in the field of pain and its support to health players". Bertrand Deluard, Ethypharm Group CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US